Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Standard
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. / Kurzweg, Thiemo; Möckelmann, Nikolaus; Laban, Simon; Knecht, Rainald.
In: EUR ARCH OTO-RHINO-L, Vol. 269, No. 10, 10, 01.10.2012, p. 2157-2167.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
AU - Kurzweg, Thiemo
AU - Möckelmann, Nikolaus
AU - Laban, Simon
AU - Knecht, Rainald
PY - 2012/10/1
Y1 - 2012/10/1
N2 - The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors. The first-line treatment of locally advanced tumor stages consists of a combined modality management. Despite these aggressive protocols, many patients develop locoregional recurrences or metastasis and place particularly high demands on the interdisciplinary treatment team. Treatment with a curative intent must be differentiated from a palliative one. In addition to prior treatment, resectability, age and performance status, patient wishes must be taken into consideration in treatment planning, especially considering that most therapies offer little to no overall survival benefit. Salvage surgery, chemo- and target therapies, and reirradiation are head and neck surgeon's and radiooncologist's weapons in the fight against these strong opponents. This review focuses on publications and meeting news from last year and reviews the current status of the clinical application of each treatment modality in recurrent or metastatic head and neck cancer.
AB - The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors. The first-line treatment of locally advanced tumor stages consists of a combined modality management. Despite these aggressive protocols, many patients develop locoregional recurrences or metastasis and place particularly high demands on the interdisciplinary treatment team. Treatment with a curative intent must be differentiated from a palliative one. In addition to prior treatment, resectability, age and performance status, patient wishes must be taken into consideration in treatment planning, especially considering that most therapies offer little to no overall survival benefit. Salvage surgery, chemo- and target therapies, and reirradiation are head and neck surgeon's and radiooncologist's weapons in the fight against these strong opponents. This review focuses on publications and meeting news from last year and reviews the current status of the clinical application of each treatment modality in recurrent or metastatic head and neck cancer.
KW - Humans
KW - Combined Modality Therapy
KW - Salvage Therapy
KW - Antibodies, Monoclonal/therapeutic use
KW - Antineoplastic Agents/therapeutic use
KW - Fluorouracil/therapeutic use
KW - Pyrimidines/therapeutic use
KW - Palliative Care
KW - Benzodioxoles/therapeutic use
KW - Carcinoma, Squamous Cell/mortality/pathology/therapy
KW - Head and Neck Neoplasms/mortality/pathology/therapy
KW - Indoles/therapeutic use
KW - Neoplasm Recurrence, Local/mortality/therapy
KW - Pyrroles/therapeutic use
KW - Quinazolines/therapeutic use
KW - Quinazolinones/therapeutic use
KW - Receptor, Epidermal Growth Factor/antagonists & inhibitors
KW - Thiazoles/therapeutic use
KW - Humans
KW - Combined Modality Therapy
KW - Salvage Therapy
KW - Antibodies, Monoclonal/therapeutic use
KW - Antineoplastic Agents/therapeutic use
KW - Fluorouracil/therapeutic use
KW - Pyrimidines/therapeutic use
KW - Palliative Care
KW - Benzodioxoles/therapeutic use
KW - Carcinoma, Squamous Cell/mortality/pathology/therapy
KW - Head and Neck Neoplasms/mortality/pathology/therapy
KW - Indoles/therapeutic use
KW - Neoplasm Recurrence, Local/mortality/therapy
KW - Pyrroles/therapeutic use
KW - Quinazolines/therapeutic use
KW - Quinazolinones/therapeutic use
KW - Receptor, Epidermal Growth Factor/antagonists & inhibitors
KW - Thiazoles/therapeutic use
U2 - 10.1007/s00405-012-1998-3
DO - 10.1007/s00405-012-1998-3
M3 - SCORING: Journal article
C2 - 22437252
VL - 269
SP - 2157
EP - 2167
JO - EUR ARCH OTO-RHINO-L
JF - EUR ARCH OTO-RHINO-L
SN - 0937-4477
IS - 10
M1 - 10
ER -
